Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) are important causes of serious infections in intensive care unit (ICU). This study aimed to investigate the risk factors for intestinal carriage of ESBL-PE among patients admitted to ICU, subsequent ESBL-PE infections, and outcomes of these patients. This study prospectively collected rectal swabs from 215 ICU patients in Northern Thailand and ESBL-PE were isolated. A high prevalence of ESBL-PE carriage (134/215, 62.3%) at ICU admission was observed, with representing the predominant organism (67.5%) followed by (19.4%). Multivariate logistic regression analysis identified chronic renal disease as the independent risk factor for ESBL-PE carriage ( = 0.009; adjusted odds ratio = 4.369; 95% confidence interval = 1.455-13.119). Among colonized patients, 2.2% (3/134) developed ESBL-PE infections during ICU stay. Phylogenetic analysis of ( = 108) showed that the predominant group was group A (38.0%), followed by groups B1 (17.6%), D (15.7%), B2 (14.8%), C (7.4%), and F (6.5%). Multilocus sequence typing analysis of the pathogenic groups B2, D, and F revealed 11 different sequence types (STs), with ST131 ( = 13) as the most prevalent, followed by ST648 ( = 5), ST38 ( = 4), ST393 ( = 3), and ST1193 ( = 3). These results are of concern since ESBL-PE may be a prerequisite for endogenous infections and potentially disseminate within the hospital. This is the first study describing ESBL-PE carriage among patients at ICU admission and subsequent ESBL-PE infections in Thailand.

Download full-text PDF

Source
http://dx.doi.org/10.1089/mdr.2018.0318DOI Listing

Publication Analysis

Top Keywords

esbl-pe infections
12
esbl-pe carriage
12
esbl-pe
10
risk factors
8
extended-spectrum β-lactamase-producing
8
β-lactamase-producing enterobacteriaceae
8
carriage patients
8
patients admitted
8
intensive care
8
care unit
8

Similar Publications

Objective: To evaluate the efficacy of piperacillin/tazobactam (PTZ) for the treatment of extended-spectrum beta-lactamase-producing enterobacteriaceae (ESBL-PE) urinary tract infections (UTIs).

Data Sources: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards on PubMed, MEDLINE, Embase, Web of Science Core Collection, and Cochrane Central through July 2024.

Study Selection And Data Extraction: Studies providing efficacy data associated with PTZ in patients ≥18 years old experiencing an ESBL-PE UTI that documented clinical and microbiological cure data were included.

View Article and Find Full Text PDF

Background: ESBL-producing Enterobacteriaceae (ESBL-PE) represent a significant global health threat. In response to this growing concern and the lack of a surveillance system for ESBL-PE infections in Egypt, we conducted this meta-analysis. In this study, we aimed to quantify the prevalence of ESBL-PE based on the source of infection and characterize their molecular dissemination.

View Article and Find Full Text PDF

Urinary tract infections: a retrospective cohort study of (mis)matching antimicrobial therapy and clinical outcome among Finnish adults.

JAC Antimicrob Resist

December 2024

Department of Infectious Diseases, Meilahti Vaccine Research Centre, MeVac, University of Helsinki and Helsinki University Hospital, P.O. Box 700, FI-00029 HUS Helsinki, Finland.

Objectives: With the global spread of antimicrobial resistance, treating urinary tract infections (UTIs) is becoming more challenging. Clinical data on UTI outcomes are scarce in cases with antimicrobial treatment mismatching the uropathogens' susceptibility profiles. We explored the association of (mis)matching antimicrobial treatment and clinical outcomes among patients with either ESBL-producing Enterobacterales (ESBL-PE) or non-ESBL-PE identified in urine samples.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the prevalence of extended-spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacterales (CPE) in HIV-infected patients at Jimma Medical Center, analyzing 344 stool samples for antibiotic-resistant bacteria.
  • A total of 376 Enterobacterales were isolated, revealing that 13.3% were ESBL producers and 4.3% were CPE, with Klebsiella pneumoniae and E. coli being the most common resistant strains.
  • Key risk factors for ESBL and CPE presence included prior use of cephalosporins, low CD4 counts, and comorbidities, highlighting the need for improved infection control and antibiotic management.
View Article and Find Full Text PDF
Article Synopsis
  • Aminoglycoside resistance is prevalent in patients with extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales, impacting the choice of empirical treatment for infections.
  • A study of 544 hospitalized patients found that 44.1% had aminoglycoside-resistant ESBL strains, particularly linked to ESBL-Klebsiella pneumoniae and recent international travel.
  • The findings highlight the necessity for clinicians to factor in the high rates of resistance when deciding on antibiotic therapy for suspected ESBL-PE infections, especially in settings with low ESBL prevalence.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!